Repurposing of FDA -approved therapeutics to identify novel radiosensitisers in hypoxic prostate cancer.
Affiliation
University of Manchester, Manchester, UKIssue Date
2018-03
Metadata
Show full item recordCitation
Repurposing of FDA -approved therapeutics to identify novel radiosensitisers in hypoxic prostate cancer. 2018, 30(3):195 Clinical OncologyJournal
Clinical OncologyDOI
10.1016/j.clon.2017.12.012Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0936655517305319Type
Meetings and ProceedingsLanguage
enISSN
09366555ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2017.12.012